GH - Guardant Health, Inc.
| Previous Close | 37.72 |
| Open | 38.49 |
| Bid | 34.00 x 2900 |
| Ask | 44.79 x 3000 |
| Day's Range | 37.77 - 43.72 |
| 52 Week Range | 27.04 - 43.80 |
| Volume | 931,165 |
| Avg. Volume | 1,817,830 |
| Market Cap | 3.403B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- American City Business Journals•3 days ago
Unicorn births outpace IPOs in Bay Area: Here are the 24 new ones so far this year
Only eight of the Bay Area's unicorns have gone public this year. Meanwhile, 24 new ones have been born. Here's a look at all of them.
- MarketWatch•14 days ago
Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early
The startup’s cancer tests help match patients with the right treatments. It also has even bigger ambitions: to use its tests to find cancer recurrences, and even for early detection of cancers.
- MarketWatch•14 days ago
Guardant Health's stock soars in public debut after IPO prices above expectations
Shares of Guardant Health Inc. soared in their public debut Thursday, as they opened 46% above the initial public offering price, which was well above the expected range. The first trade for the cancer detection and treatment company's stock was at $27.75 at 10:48 a.m. ET for 1.7 million shares. That compares with the IPO price of $19, which was above the expected range of $15 to $17. The stock has extended gains since then, to trade up 51%. The company raised $237.5 million with the IPO, which values the company at $1.6 billion. Guardant is going public at a time that the Renaissance IPO ETF has slipped 0.9% over the past three months, while the iShares Nasdaq Biotechnology ETF has gained 7.5% and the S&P 500 has advanced 7.1%.
- MarketWatch•14 days ago
Guardant Health IPO prices above expected range to value company at $1.6 billion
Guardant Health Inc. said Thursday its initial public offering of 12.5 million shares priced at $19 a share, above the expected range of $15 to $17 a share, to raise $237.5 million. If the underwriters exercise all the options granted to buy additional shares, oncology company could raise up to $273.1 million. The IPO pricing values the Redwood City, Calif.-based company at $1.59 billion. The company had a net loss of $83.2 million on revenue of $49.8 million in 2017, compared with a loss of $46.1 million and revenue of $25.2 million in 2016. The stock is expected to begin trading Thursday on the Nasdaq under the ticker symbol "GH." The company is going public at a time that the Renaissance IPO ETF has gained 5.0% year to date and the S&P 500 has gained 9.4%.
- Benzinga•18 days ago
IPO Outlook For The Week: Diagnostics, Data Miners And Freelance Facilitators
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Upwork Inc. (UPWK) will issue nearly 12.3 million shares between $10 and $12 Wednesday on the Nasdaq. Upwork’s online platform ...
